Physician profile
Samuel O Makanjuola
NPI 1962089904
$2,017.35
in general payments reported to CMS, 2019-2025
13 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $143 · 2024: $1,153 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $446.91 | 2024-2025 | Prostep Mica, Variax, Citrefix |
| Abbott Laboratories | $270.60 | 2024-2025 | Jeti All In One Non-Sterile Kit, Eterna |
| Avita Medical Americas, LLC | $229.07 | 2024 | |
| Amgen INC. | $212.60 | 2025 | Krystexxa |
| Medtronic, INC. | $164.02 | 2025 | In.Pact Admiral, Inceptiv |
| Inari Medical, INC. | $124.97 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ani Pharmaceuticals, INC. | $122.04 | 2024 | Purified Cortrophin Gel |
| Smith+Nephew, INC. | $119.64 | 2024 | Grafix Pl |
| Paratek Pharmaceuticals, INC. | $102.40 | 2024 | Nuzyra |
| Cosa Medical, LLC | $25.62 | 2025 | |
| Abbvie INC. | $23.63 | 2024 | |
| Convatec INC. | $23.55 | 2024 | |
| Orthofix Medical, INC. | $8.82 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Makanjuola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.